Author: K-STOCK Editor

[Disclosure] Samsung Biologics (207940) – Submission of Audit Report / 2025-02-25

[Disclosure] Samsung Biologics (207940) – Submission of Audit Report / 2025-02-25

Disclosures

[Disclosure] Celltrion (068270) – Change in Revenue or Profit/Loss Structure Exceeding 15% / 2025-02-25

[Disclosure] Celltrion (068270) – Change in Revenue or Profit/Loss Structure Exceeding 15% / 2025-02-25

Disclosures

[Disclosure] Celltrion (068270) – Provisional Separate Financial Results / 2025-02-25

[Disclosure] Celltrion (068270) – Provisional Separate Financial Results / 2025-02-25

Disclosures

[Disclosure] Celltrion (068270) – Provisional Consolidated Financial Results / 2025-02-25

[Disclosure] Celltrion (068270) – Provisional Consolidated Financial Results / 2025-02-25

Disclosures

[Disclosure] Celltrion (068270) – Resolution on Convening Annual General Meeting of Shareholders / 2025-02-25

[Disclosure] Celltrion (068270) – Resolution on Convening Annual General Meeting of Shareholders / 2025-02-25

Disclosures

[Disclosure] LEENO Industrial (058470) – Resolution on Convocation of Annual General Meeting of Shareholders / 2025-02-25

[Disclosure] LEENO Industrial (058470) – Resolution on Convocation of Annual General Meeting of Shareholders / 2025-02-25

Semiconductors

[Disclosure] Hanwha Aerospace (012450) – Decision on General Meeting of Shareholders / 2025-02-24

[Disclosure] Hanwha Aerospace (012450) – Decision on General Meeting of Shareholders / 2025-02-24

Disclosures

[Disclosure] Hanwha Aerospace (012450) – Decision on Cash Dividends / 2025-02-24

[Disclosure] Hanwha Aerospace (012450) – Decision on Cash Dividends / 2025-02-24

Disclosures

[Disclosure] Jeju Semiconductor (080220) – (Correction) Decision on Issuance of Convertible Bonds (8th Series) / 2025-02-24

[Disclosure] Jeju Semiconductor (080220) – (Correction) Decision on Issuance of Convertible Bonds (8th Series) / 2025-02-24

Semiconductors

[Disclosure] Celltrion (068270) – Approval of Phase 3 Clinical Trial Application for CT-P13 SC (Remsima Subcutaneous) in Pediatric Ulcerative Colitis in Korea / 2025-02-24

[Disclosure] Celltrion (068270) – Approval of Phase 3 Clinical Trial Application for CT-P13 SC (Remsima Subcutaneous) in Pediatric Ulcerative Colitis in Korea / 2025-02-24

Disclosures